• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Edwards Lifesciences Corporation

    8/6/25 5:26:33 PM ET
    $EW
    Industrial Specialties
    Health Care
    Get the next $EW alert in real time by email
    S-8 1 d39572ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on August 6, 2025

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    EDWARDS LIFESCIENCES CORPORATION

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   36-4316614

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    One Edwards Way

    Irvine, California 92614

    (Address, including zip code, of Principal Executive Offices)

     

     

    Edwards Lifesciences Corporation

    2001 Employee Stock Purchase Plan for International Employees

    (Full title of the plan)

     

     

    Mark D. Peterson

    Corporate Vice President, General Counsel

    Edwards Lifesciences Corporation

    One Edwards Way

    Irvine, California 92614

    (949) 250-2500

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     

     


    EXPLANATORY NOTE

    This Registration Statement is filed by Edwards Lifesciences Corporation (the “Company” or “Registrant”) to register additional securities issuable pursuant to the Edwards Lifesciences Corporation 2001 Employee Stock Purchase Plan for International Employees, as amended and restated, and consists of only those items required by General Instruction E to Form S-8.

     

     

    PART I

    INFORMATION REQUIRED IN THE

    SECTION 10(a) PROSPECTUS

    The document(s) containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Rule 428(b)(1) promulgated under the Securities Act of 1933, as amended (the “Securities Act”).

     

    2


    PART II

    INFORMATION REQUIRED IN THE

    REGISTRATION STATEMENT

     

    Item 3.

    Incorporation of Certain Documents by Reference

    The following documents of the Company filed with the Securities and Exchange Commission (the “Commission”) are incorporated herein by reference:

     

      (a)

    The Company’s Registration Statement on Form S-8, filed with the Commission on May 7, 2021 (Commission File No. 333-255854);

     

      (b)

    The Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2024, filed with the Commission on February 28, 2025 (Commission File No. 001-15525);

     

      (c)

    The portions of the Company’s Definitive Proxy Statement on Schedule 14A, filed with the Commission on March  26, 2025, that are incorporated by reference in Part III of the Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2024 (Commission File No. 001-15525);

     

      (d)

    The Company’s Quarterly Reports on Form 10-Q for its fiscal quarters ended March 31, 2025 and June 30, 2025, filed with the Commission on May  6, 2025 and August 6, 2025, respectively (each, Commission File No. 001-15525);

     

      (e)

    The Company’s Current Reports on Form 8-K, filed with the Commission on May  8, 2025 and July 25, 2025 (each, Commission File No. 001-15525); and

     

      (f)

    The description of the Company’s Common Stock contained in Exhibit 4.2 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Commission on February 13, 2023, which updated the description thereof contained in Post-Effective Amendment No. 1 to the Company’s Registration Statement on Form 10, filed with the Commission on April 5, 2000 (each, Commission File No. 001-15525), and any other amendments or reports filed for the purpose of updating such description.

    All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

     

    3


    Item 5.

    Interests of Named Experts and Counsel

    The validity of the issuance of Common Stock registered hereby is passed on for the Company by Linda J. Park. Ms. Park is the Company’s Senior Vice President, Associate General Counsel and Corporate Secretary and is compensated by the Company as an employee. Ms. Park has participated in and holds awards granted under the Company’s equity and long-term compensation plans and owns shares of Common Stock.

     

    Item 8.

    Exhibits

    See the attached Exhibit Index at page 5, which is incorporated herein by reference.

     

    4


    EXHIBIT INDEX

     

    Exhibit
    Number

      

    Description of Exhibit

    4    Edwards Lifesciences Corporation 2001 Employee Stock Purchase Plan for International Employees, as amended and restated February 13, 2025 (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for its fiscal quarter ended June 30, 2025, filed with the Commission on August 6, 2025 (Commission File No. 001-15525)).
    5    Opinion of Counsel (opinion re legality).
    23.1    Consent of PricewaterhouseCoopers LLP (consent of independent registered public accounting firm).
    23.2    Consent of Counsel (included in Exhibit 5).
    24    Power of Attorney (included in this Registration Statement under “Signatures”).
    107    Filing Fee Table

     

    5


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Form S-8 Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on August 6, 2025.

     

    EDWARDS LIFESCIENCES CORPORATION
    By:  

    /s/ Linda J. Park

      Linda J. Park
      Senior Vice President, Associate General Counsel, and Corporate Secretary

     

    6


    POWER OF ATTORNEY

    Each person whose signature appears below constitutes and appoints Scott B. Ullem, Mark Peterson, and Linda J. Park, and each of them, acting individually and without the other, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto and other documents in connection therewith) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them individually, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

      

    Date

    /s/ Bernard J. Zovighian

    Bernard J. Zovighian

      

    Chief Executive Officer

    (Principal Executive Officer)

       August 6, 2025

    /s/ Scott B. Ullem

    Scott B. Ullem

      

    Corporate Vice President and Chief Financial Officer

    (Principal Financial Officer)

       August 6, 2025

    /s/ Andrew M. Dahl

    Andrew M. Dahl

      

    Senior Vice President, Corporate Controller

    (Principal Accounting Officer)

       August 6, 2025

    /s/ Leslie C. Davis

    Leslie C. Davis

       Director    August 6, 2025

    /s/ David T. Feinberg

    David T. Feinberg

       Director    August 6, 2025

    /s/ Kieran T. Gallahue

    Kieran T. Gallahue

       Director    August 6, 2025

    /s/ Leslie S. Heisz

    Leslie S. Heisz

       Director    August 6, 2025

    /s/ Paul A. LaViolette

    Paul A. LaViolette

       Director    August 6, 2025

     

    7


    Signature

      

    Title

      

    Date

    /s/ Steven R. Loranger

    Steven R. Loranger

       Director    August 6, 2025

    /s/ Ramona Sequeira

    Ramona Sequeira

       Director    August 6, 2025

    /s/ Nicholas J. Valeriani

    Nicholas J. Valeriani

       Director    August 6, 2025

     

     

    8

    Get the next $EW alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EW

    DatePrice TargetRatingAnalyst
    7/29/2025$100.00Neutral → Buy
    BTIG Research
    4/24/2025$80.00Neutral → Overweight
    Piper Sandler
    1/30/2025$75.00 → $90.00Hold → Buy
    Stifel
    1/16/2025$60.00Peer Perform → Underperform
    Wolfe Research
    12/16/2024Neutral → Buy
    BofA Securities
    10/11/2024$70.00Equal-Weight
    Morgan Stanley
    9/18/2024$85.00 → $70.00Buy → Hold
    Jefferies
    7/31/2024Neutral → Outperform
    Daiwa Securities
    More analyst ratings

    $EW
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Edwards Lifesciences Corporation

    SCHEDULE 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

    8/12/25 10:34:25 AM ET
    $EW
    Industrial Specialties
    Health Care

    SEC Form S-8 filed by Edwards Lifesciences Corporation

    S-8 - Edwards Lifesciences Corp (0001099800) (Filer)

    8/6/25 5:28:07 PM ET
    $EW
    Industrial Specialties
    Health Care

    SEC Form S-8 filed by Edwards Lifesciences Corporation

    S-8 - Edwards Lifesciences Corp (0001099800) (Filer)

    8/6/25 5:26:33 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Global President TAVR & Surg Wood Larry L sold $698,679 worth of shares (8,950 units at $78.06) and exercised 8,950 shares at a strike of $59.26 (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    8/18/25 6:11:18 PM ET
    $EW
    Industrial Specialties
    Health Care

    CVP, JAPAC Lippis Daniel J. sold $326,900 worth of shares (4,114 units at $79.46), decreasing direct ownership by 16% to 22,002 units (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    7/28/25 6:23:58 PM ET
    $EW
    Industrial Specialties
    Health Care

    CVP, EMEACLA Bruls Annette covered exercise/tax liability with 109 shares, decreasing direct ownership by 0.76% to 14,171 units (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    7/11/25 5:43:52 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Zovighian Bernard J covered exercise/tax liability with 4,245 shares, converted options into 6,265 shares and bought $49,753 worth of shares (580 units at $85.74), increasing direct ownership by 5% to 46,836 units (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    5/7/24 5:53:27 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Edwards Lifesciences upgraded by BTIG Research with a new price target

    BTIG Research upgraded Edwards Lifesciences from Neutral to Buy and set a new price target of $100.00

    7/29/25 7:23:34 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Edwards Lifesciences from Neutral to Overweight and set a new price target of $80.00

    4/24/25 7:18:16 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences upgraded by Stifel with a new price target

    Stifel upgraded Edwards Lifesciences from Hold to Buy and set a new price target of $90.00 from $75.00 previously

    1/30/25 7:10:09 AM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Edwards Lifesciences Comments on FTC's Action to Block Proposed Acquisition of JenaValve

    Edwards Lifesciences (NYSE:EW) announced today that the U.S. Federal Trade Commission (FTC) moved to block the company's proposed acquisition of JenaValve Technology. Edwards disagrees with FTC's decision and believes it will limit the availability of an important treatment option for patients suffering from aortic regurgitation (AR). The company further believes the acquisition of JenaValve will accelerate the availability, adoption and continued innovation of a life-saving treatment for patients suffering from AR. AR is a deadly and progressive disease that affects a significant and growing number of patients, many of whom currently have limited treatment options. Edwards intends to

    8/6/25 1:40:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences Reports Second Quarter Results

    Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights Q2 sales grew 11.9% to $1.53 billion, or 10.6% adjusted1, with strength across all product groups Q2 TAVR sales grew 8.9%; constant currency1 sales grew 7.8% Q2 TMTT sales reached $134.5 million or $133.0 million adjusted1, driven by PASCAL and EVOQUE Q2 EPS of $0.572; adjusted1 EPS of $0.67 SAPIEN platform is only TAVR approved for asymptomatic patients in U.S. and now in Europe EuroPCR data confirm clinical and economic advantages of timely treatment for severe AS patients 10-year data from PARTNER II study confirm long-term outcomes and durability

    7/24/25 4:15:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences to Host Earnings Conference Call on July 24, 2025

    Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended June 30, 2025 after the market closes on Thursday July 24, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and

    7/18/25 7:05:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Leadership Updates

    Live Leadership Updates

    View All

    Scaling its Investment Platform in Minimally Invasive Care, Intuitive Ventures Appoints Terri Burke as Senior Partner and Ross Jaffe as Venture Advisor

    Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner and Dr. Ross Jaffe, a co-founder of Versant Ventures, as Venture Advisor. Both medtech veterans, they will help support the continued growth of Intuitive Ventures in investing in start-ups reimagining the future of minimally invasive care. With more than two decades of medtech investing and operational leadership experience, Burke will help support the growth of the firm's investment platform. With over $250 million in assets under management, Intuitive Ventures invests in founders tackling large, meaningful problems that positive

    3/6/25 8:00:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    EDWARDS LIFESCIENCES ANNOUNCES CEO SUCCESSION PLAN

    IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced that following regular succession planning discussions with the Board of Directors, Edwards' chairman and CEO, Michael A. Mussallem, who recently turned 70, has informed the Board of his decision to retire as CEO in connection with the company's Annual Meeting of Stockholders on May 11, 2023. At the 2023 annual meeting, Mussallem will stand for election as non-executive chairman of Edwards' Board. He will be succeeded as CEO by Bernard Zovighian, currently corporate vice pre

    12/8/22 8:00:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Announces Updates From Annual Meeting

    IRVINE, Calif., May 5, 2021 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced updates from its annual meeting, in which Edwards' stockholders voted with the board's recommendations on all proxy proposals: All eight director nominees were elected as directors of the company for a one-year term; Stockholders advised that they approve the compensation of the company's named executive officers; Stockholders have approved the Amendment and Restatement of the company's U.S. and International Employee Stock Purchase Plans; Stockholders have ratified the appoi

    5/5/21 9:15:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Edwards Lifesciences Corporation

    SC 13G - Edwards Lifesciences Corp (0001099800) (Subject)

    11/8/24 10:34:33 AM ET
    $EW
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Edwards Lifesciences Corporation

    SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

    10/4/24 2:14:28 PM ET
    $EW
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Edwards Lifesciences Corporation (Amendment)

    SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

    2/13/24 5:04:42 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Financials

    Live finance-specific insights

    View All

    Edwards Lifesciences Reports Second Quarter Results

    Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights Q2 sales grew 11.9% to $1.53 billion, or 10.6% adjusted1, with strength across all product groups Q2 TAVR sales grew 8.9%; constant currency1 sales grew 7.8% Q2 TMTT sales reached $134.5 million or $133.0 million adjusted1, driven by PASCAL and EVOQUE Q2 EPS of $0.572; adjusted1 EPS of $0.67 SAPIEN platform is only TAVR approved for asymptomatic patients in U.S. and now in Europe EuroPCR data confirm clinical and economic advantages of timely treatment for severe AS patients 10-year data from PARTNER II study confirm long-term outcomes and durability

    7/24/25 4:15:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences to Host Earnings Conference Call on July 24, 2025

    Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended June 30, 2025 after the market closes on Thursday July 24, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and

    7/18/25 7:05:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences Reports First Quarter Results

    Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted1 Q1 TAVR sales grew 3.8%; constant currency1 sales grew 5.4%, better than expected Q1 TMTT sales grew 58% to $115 million with meaningful contribution to Edwards' growth Q1 EPS of $0.622; adjusted1 EPS of $0.64 SAPIEN M3 CE Mark approval uniquely positions Edwards with a comprehensive TMTT portfolio NCD finalized for transcatheter tricuspid valve replacement, expanding patient access to EVOQUE Multiple TAVR studies presented at ACC confirm the need for urgent patient referral to Heart Team Data from Hear

    4/23/25 4:15:00 PM ET
    $EW
    Industrial Specialties
    Health Care